We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+67.56%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$955M
AUM Growth
+$389M
(+69%)
Cap. Flow
+$199M
Cap. Flow
% of AUM
20.8%
Top 10 Holdings %
Top 10 Hldgs %
58.81%
Holding
63
New
12
Increased
9
Reduced
11
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$78.8M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$55.5M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$26.9M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$26.4M |
| 5 |
InflaRx
IFRX
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
+$43.2M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$27M |
| 3 |
Omeros
OMER
|
+$15.5M |
| 4 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$11.9M |
| 5 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONSIZ
51
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
| $9K | ﹤0.01% |
416,666
| – | – |
|
|
CLRBW
52
DELISTED
Cellectar Biosciences, Inc.
CLRBW
| $5K | ﹤0.01% |
52,999
| – | – |
|
53
Curis
CRIS
$9.67M
| – | – |
-575
| Closed | -$1.71M |
|
54
CytomX Therapeutics
CTMX
$714M
| – | – |
-100,000
| Closed | -$1.82M |
|
|
NVRO
55
DELISTED
NEVRO CORP.
NVRO
| – | – |
-100,000
| Closed | -$9.09M |
|
|
EGRX
56
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| – | – |
-200,000
| Closed | -$11.9M |
|
|
CBAY
57
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-500,000
| Closed | -$4.03M |
|
|
AGRX
58
DELISTED
Agile Therapeutics
AGRX
| – | – |
-625
| Closed | -$5.58M |
|
|
PTLA
59
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-500,000
| Closed | -$27M |
|
|
ALDR
60
DELISTED
Alder Biopharmaceuticals
ALDR
| – | – |
-900,000
| Closed | -$11M |
|
|
AAAP
61
DELISTED
Advanced Accelerator Applications S.A.
AAAP
| – | – |
-75,000
| Closed | -$5.07M |
|
|
RXDX
62
DELISTED
Ignyta, Inc.
RXDX
| – | – |
-3,500,000
| Closed | -$43.2M |
|
|
IMDZ
63
DELISTED
Immune Design Corp.
IMDZ
| – | – |
-280,500
| Closed | -$2.9M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q4 2017 Portfolio in Review
As of Q4 2017, Cormorant Asset Management held 63 positions worth $955M, up 69% from $566M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Cormorant Asset Management deployed $199M of net new capital in Q4 2017, opening 12 new positions and adding to 9 existing holdings. Its largest new stake was Nektar Therapeutics: 133,180 shares worth $119M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 87% a quarter earlier.
On the sell side, the largest reduction was Omeros, an estimated $15.5M trimmed.
- Cormorant Asset Management's largest Q4 2017 buy was Nektar Therapeutics: 133,180 shares worth $119M.
- Cormorant Asset Management added most to Blueprint Medicines in Q4 2017, an estimated $26.4M increase.
- Cormorant Asset Management's biggest Q4 2017 reduction was Omeros, cutting an estimated $15.5M.
- Cormorant Asset Management fully exited Ignyta, Inc. in Q4 2017, selling an estimated $43.2M.
- Cormorant Asset Management's ten largest holdings make up 59% of its $955M portfolio in Q4 2017.
- Cormorant Asset Management opened 12 new positions and closed 11 in Q4 2017.
- Cormorant Asset Management's portfolio value rose 69% quarter-over-quarter to $955M.
Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.